The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

LITESPARK-029: A phase 2, randomized, open-label study of belzutifan plus fulvestrant in participants with estrogen receptor–positive, HER2-negative unresectable locally advanced or metastatic breast cancer after progression on previous endocrine therapy.

Bora  Lim

Honoraria - Department of Defense; SABCS

Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; Natera; Novartis

Research Funding - Calithera Biosciences; Genentech; Merck; Puma Biotechnology; Takeda

Liyi  Jia

Employment - Merck Sharp & Dohme

Stock and Other Ownership Interests  - Merck

Preeti  Sudheendra

Employment - Merck

Honoraria - Medtronic (I)

Kim  Hirshfield

Employment - Merck Sharp & Dohme

Stock and Other Ownership Interests  - Merck